Informační systém MU
BIENERTOVÁ VAŠKŮ, Julie, Alena LUNGOVÁ, Petr BIENERT, Filip ZLÁMAL, Josef TOMANDL, Marie TOMANDLOVÁ, Zbyněk ŠPLÍCHAL and Jaroslav ŠTĚRBA. Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia. Klinická onkologie. Praha: Ambit Media a.s., 2012, vol. 25, Supplement 2, p. 58– 63. ISSN 0862-495X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia
Authors BIENERTOVÁ VAŠKŮ, Julie (203 Czech Republic, guarantor, belonging to the institution), Alena LUNGOVÁ (203 Czech Republic), Petr BIENERT (203 Czech Republic, belonging to the institution), Filip ZLÁMAL (203 Czech Republic, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Marie TOMANDLOVÁ (203 Czech Republic, belonging to the institution), Zbyněk ŠPLÍCHAL (203 Czech Republic, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic).
Edition Klinická onkologie, Praha, Ambit Media a.s. 2012, 0862-495X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/12:00063158
Organization unit Faculty of Medicine
Keywords (in Czech) faktor aktivující B buňky (BAFF); nádorová kachexie; nádorové onemocnění; pediatrická onkologie
Keywords in English B cell-activating factor; cachexia; cancer; paediatrics
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 28. 1. 2013 15:15.
Abstract
Cancer-related cachexia is a multifactorial syndrome characterised by progressive loss of body weight and it affects a large proportion of patients with advanced cancer. Cachexia is associated with reduced treatment tolerance, response to therapy, quality of life and duration of survival, whereas some of its mechanisms are shared across the whole continuum of diseases in the population, either cancer-related or non-cancer related e.g. systemic inflammation, increased lipolysis, insulin resistance and reduced physical performance. However, so far there has been only little effort to utilise the integrative physiology of adipose tissue to achieve therapeutic gain. B cell-activating factor (BAFF) is a novel member of the TNF ligand superfamily, is mainly produced by myeloid cells and has recently been shown to participate in B-cell survival and B- and T-cell maturation, but also in adipogenesis. Therefore, it represents an elegant candidate molecule linking the immune system and adipose tissue metabolism, both being involved deeply in the pathogenesis of cachexia. Moreover, it has been described very recently that BAFF directly influences secretion of IL-6 and IL-10.
Displayed: 27. 6. 2022 02:10